Karl-Anthony Towns Partners with Sanofi to Promote COVID-19 Vaccination Awareness

Karl-Anthony Towns and Sanofi Join Forces for COVID-19 Vaccination Awareness

In an effort to combat COVID-19, Sanofi has partnered with the renowned NBA champion Karl-Anthony Towns. As a key figure in sports and a survivor of the effects of COVID-19, Towns aims to raise awareness about the importance of COVID-19 vaccination, particularly during the upcoming respiratory season. This initiative features the NUVAXOVID vaccine— the only protein-based, non-mRNA COVID-19 vaccine that is FDA-approved.

Towns, a six-time NBA All-Star and the 2016 NBA Rookie of the Year, shares his personal experience with the virus to encourage those at risk to seek information about their vaccination options. He emphasizes that protecting one’s health is paramount, especially as respiratory illness seasons approach.

Through various digital and social media campaigns, Towns stresses the need for candid discussions with healthcare providers concerning vaccination choices, particularly highlighting NUVAXOVID. This vaccine employs recombinant protein technology, similar to some existing modern flu vaccines, offering a unique approach to boosting protection against COVID-19.

According to Towns, “COVID-19 affected my family profoundly, shaping my perspective on health. With the upcoming basketball season and the respiratory virus season, I prioritize protecting myself. It’s essential for individuals, especially those at heightened risk, to have informed conversations with their healthcare providers regarding vaccination.”

NUVAXOVID is specifically designed for adults aged 65 and older and individuals between 12 and 64 who have underlying conditions that increase their risk of severe COVID-19 outcomes. In clinical trials, side effects reported were generally mild, allowing individuals to continue their daily routines without interruption.

Kimberly Tutwiler, the Head of Vaccines for North America at Sanofi, expresses, “Karl-Anthony provides an authentic voice to raise awareness about the COVID-19 vaccination. With many eligible individuals still unvaccinated, it's vital to help people comprehend their vaccination options.”

The campaign aims to educate the public about the ongoing risks that COVID-19 poses, urging individuals to prioritize preventative health measures. As the virus continues its circulation, vulnerable populations, particularly seniors and those with chronic health conditions, are at heightened risk.

Incorporating NUVAXOVID into local and seasonal vaccination programs is part of a broader public health strategy aimed at increasing access to diverse vaccine options. This variety may help alleviate vaccine hesitancy within communities.

Sanofi has commenced expanding NUVAXOVID’s availability beyond the U.S. to additional regions, including the U.K., Germany, and Canada. As the market authorization holder, Sanofi is dedicated to ensuring that NUVAXOVID can be an integral part of efforts to protect communities against COVID-19.

Individuals interested in learning more about NUVAXOVID and whether it’s right for them can consult their healthcare providers or pharmacists. More information can be found at NUVAXOVID.com on vaccine availability and other options.

Karl-Anthony Towns continues to represent the importance of protecting health within and beyond the athletic community, inspiring many to prioritize vaccinations. In his words, “Taking these steps can make a difference not just for ourselves but for our loved ones and our communities.”